Results 31 to 40 of about 886,649 (291)
Haematologica, 2019 Clonal chromosome abnormalities in Philadelphia-negative cells could concern chronic myeloid leukemia patients treated by tyrosine kinase inhibitors. The European LeukemiaNet distinguishes -7/del(7q) abnormalities as a “warning”.
Audrey Bidet +32 more
doaj +1 more source
Frontiers in Genetics, 2022 We aim to determine the spectrum of cytogenetic abnormalities and outcomes in unbalanced offspring of asymptomatic constitutional balanced t(9;22) carriers through a systematic literature review. We also include a case of a constitutional balanced t(9;22)
Zimeng Gao +8 more
doaj +1 more source
Blood Advances, 2020 Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell acute lymphoblastic leukemia in older children, adolescents, and adults and is associated with high rates of conventional treatment failure ...
R. Harvey, S. Tasian
semanticscholar +1 more source
Neoplasia: An International Journal for Oncology Research, 1999 We have investigated a single telomere expansion in a case of acute lymphoblastic B-cell leukemia (B-ALL), where half of the cells in the bone marrow sample appeared with a Philadelphia chromosome. Comparing telomere sizes in Philadelphia-positive versus
Katerina Krejcí +2 more
doaj +1 more source
On-line Viterbi Algorithm and Its Relationship to Random Walks [PDF]
Algorithms in Bioinformatics: 7th International Workshop (WABI),
4645 volume of Lecture Notes in Computer Science, pp. 240-251, Philadelphia,
PA, USA, September 2007. Springer, 2007 In this paper, we introduce the on-line Viterbi algorithm for decoding hidden Markov models (HMMs) in much smaller than linear space. Our analysis on two-state HMMs suggests that the expected maximum memory used to decode sequence of length $n$ with $m$-state HMM can be as low as $\Theta(m\log n)$, without a significant slow-down compared to the ...
arxiv +1 more source
Blood, 2018 Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1T315I The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 ...
Jordi Cortés +28 more
semanticscholar +1 more source
Acta Haematologica, 2020 Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes.
A. Maiti +16 more
semanticscholar +1 more source
Blood, 2020 The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) with high-risk (HR) features and adequate measurable residual disease (MRD) clearance ...
J. Ribera +50 more
semanticscholar +1 more source
Response to “Philadelphia chromosome?” [PDF]
American Journal of Hematology, 2006 WOS ...
openaire +3 more sources
Cancer, 2020 Patients with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options.
W. Stock +15 more
semanticscholar +1 more source